Iain FeeneyChief Editor and CEOIain Feeney founded Stacklumen, which makes Comlumen, and leads Comlumen as Chief Editor and CEO.
Desk stories are compiled from the reporting and official sources they link, and written with AI assistance.
Support: support@
National Human Genome Research Institute, public domain A one-off infusion of an experimental base-editing therapy corrected more than half of the faulty gene copies in a 66-year-old man's liver. The peer-reviewed evidence so far is that single case.
A one-off infusion of an experimental base-editing therapy corrected more than half of the faulty gene copies in a 66-year-old man's liver. The peer-reviewed evidence so far is that single case.